Filing Summary
Business Context and Reporting Period
Ginkgo Bioworks Holdings, Inc. filed this Form 8-K under Item 8.01 and Item 9.01. The report date is November 23, 2021, and the filing was signed November 24, 2021. The filing primarily documents the post-business-combination corporate structure and provides audited consolidated financial statements for the years ended December 31, 2020 and 2019.
- On September 16, 2021, Soaring Eagle Acquisition Corp. completed its domestication and merger with Ginkgo Bioworks, Inc.
- Soaring Eagle was renamed Ginkgo Bioworks Holdings, Inc., and Ginkgo Bioworks, Inc. became its wholly owned subsidiary.
- Class A common stock and public warrants trade on the NYSE under the symbols DNA and DNA.WS, respectively.
Financial Metrics and Accounting Treatment
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. It attaches audited consolidated financial statements for 2020 and 2019 as Exhibit 99.1, but those statements are not included in the provided filing text.
The business combination was accounted for as a reverse recapitalization under U.S. GAAP. For accounting and financial reporting purposes, Ginkgo was treated as the accounting acquirer, while Soaring Eagle was treated as the acquired company. The transaction was accounted for as Ginkgo issuing stock for Soaring Eagle’s net assets, accompanied by a recapitalization.
Material Changes Versus the Prior Comparable Period
- The transaction changed the company’s legal identity, ownership structure, and public listing status but did not represent an acquisition of Ginkgo’s operating business for accounting purposes.
- Ginkgo’s historical financial statements remain the basis for the company’s continuing operations and reporting.
- Shares, corresponding capital amounts, and loss per share related to Ginkgo’s pre-transaction convertible preferred stock and common stock were retroactively restated using the merger exchange ratio of 49.080452.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide management guidance, financial outlook, forecasts, new risk factors, debt contingencies, or liquidity commentary.
The principal unusual item is the reverse recapitalization and related retroactive restatement of historical share and per-share information. Investors should also note that the filing reflects the transition from Soaring Eagle Acquisition Corp. to the publicly traded Ginkgo Bioworks Holdings structure.
Important Facts to Verify
- Review Exhibit 99.1 for audited 2019 and 2020 revenue, operating results, cash flows, balance-sheet liquidity, debt, and disclosures.
- Confirm the accounting impact of the reverse recapitalization and the 49.080452 exchange ratio on historical share counts and loss per share.
- Verify the terms and potential dilution associated with the DNA.WS public warrants, including the $11.50 exercise price.
- Confirm the September 16, 2021 closing date and the resulting legal ownership and reporting structure.
- Review subsequent filings for post-combination operating performance, capital resources, guidance, and risk disclosures.